The Manufacturers Life Insurance Company Grows Stock Position in ICU Medical, Inc. $ICUI

Posted by Stanley Muller on Aug 2nd, 2026

The Manufacturers Life Insurance Company increased its position in ICU Medical, Inc. (NASDAQ:ICUI – Free Report) by 1,394.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 170,418 shares of the medical instruments supplier’s stock after buying an additional 159,011 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in ICU Medical were worth $22,009,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ICUI. Hilton Head Capital Partners LLC acquired a new stake in shares of ICU Medical during the fourth quarter worth approximately $32,000. Covestor Ltd boosted its holdings in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares during the period. Strs Ohio increased its stake in ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of ICU Medical during the fourth quarter worth $120,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ICUI. KeyCorp raised their price target on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Wednesday, May 27th. Weiss Ratings upgraded shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. BTIG Research began coverage on ICU Medical in a research note on Monday, June 15th. They issued a “buy” rating and a $170.00 target price for the company. Finally, Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $172.00.

Read Our Latest Analysis on ICUI

ICU Medical Stock Up 0.1%

ICUI stock opened at $168.51 on Friday. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $170.81. The firm’s 50-day simple moving average is $148.01 and its 200 day simple moving average is $140.30. The stock has a market cap of $4.21 billion, a PE ratio of 91.09, a price-to-earnings-growth ratio of 2.35 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI – Get Free Report) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm had revenue of $525.77 million during the quarter, compared to analyst estimates of $520.65 million. During the same period in the previous year, the business posted $1.72 EPS. ICU Medical’s revenue was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts predict that ICU Medical, Inc. will post 6.51 EPS for the current year.

Insider Buying and Selling

In other news, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. The trade was a 23.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.10% of the company’s stock.

ICU Medical Company Profile

(Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.